You are here

Mary Kate Siebenaler, MD

Assistant Professor of Clinical Pediatrics - Hospital Medicine

About

Mary Kate Siebenaler, MD, is an Assistant Professor of Pediatrics at SIU School of Medicine. She completed a residency at the University of California San Diego after earning her medical degree at Loyola University of Chicago. She earned a bachelor of science degree with honors at University of Illinois at Urbana-Champaign. She is also board certified by the American Board of Pediatrics. She is committed to excellence in teaching and education as is evidenced by her Kaiser Excellence in Teaching Award (UCSD, 2015), and Outstanding Achievement for Medical Student Education awards (University of Florida, 2016, 2017, 2018), and Teacher of the Year awards in 2017 and 2018.

Education

School: 
University of Illinois at Urbana-Champaign, Bachelors of Science
Medical School: 
Loyola University of Chicago - Stritch School of Medicine, Chicago, IL
Residency: 
University of California San Diego - Pediatrics
Fellowship: 
University of California San Diego/ Rady Children's Hospital San Diego - Pediatric Hospital Medicine

Grants

“An Open-label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin Single-Dose Infusion in Pediatric Subjects < 18 Years of Age with Suspected or Confirmed Bacterial Infections.” University of California San Diego, School of Medicine, San Diego, CA. Role: sub-investigator, 10-2014 – 06-2015
• “A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy.” UF Child Research Institute, Gainesville, FL. Role: sub-investigator, 07-2017 – 06-2018
• “A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy.” UF Child Research Institute, Gainesville, FL. Role: sub-investigator, 07-2017 – 06-2018
• “An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early-Stage Duchenne Muscular Dystrophy.” UF Child Research Institute, Gainesville, FL. Role: sub-investigator, 07-2017 –06-2018
• “An Open-Label, Multicenter, Study with a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy.” UF Child Research Institute, Gainesville, FL. Role: sub-investigator, 07-2017 – 06-2018
• “A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with Duchenne muscular dystrophy.” UF Child Research Institute, Gainesville, FL. Role: sub-investigator, 07-2017 – 06-2018

Tabs